Back to Ovarian Cancer
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT01333748

NCT01333748
Completed Phase 2

Who may be able to join

Who might be able to join this trial:

For patients:

  • You are a woman who has been diagnosed with breast cancer and/or ovarian cancer, and your doctors believe your cancer may run in the family
  • You have already been tested for changes in the BRCA1 and BRCA2 genes, but no harmful change was found
  • You are 18 years old or older
  • You are willing to take part in the study and have signed a consent form

For the comparison group (women without cancer):

  • You are a woman with no personal history of breast or ovarian cancer, and no close relatives (parents, siblings, children, grandparents, aunts/uncles) who developed breast cancer before age 50 or ovarian cancer before age 60
  • You are willing to take part in the study and have signed a consent form

Who may not be able to join:

For patients:

  • You already have a confirmed harmful change (mutation) in the BRCA1 or BRCA2 genes
  • Your cancer does not show signs of being hereditary or running in the family
  • You are currently under legal guardianship or have restrictions on your personal freedom (confirm with trial site)

For the comparison group:

  • Men are not eligible for the comparison group
  • You have a personal or family history of breast cancer (in a close relative before age 50) or ovarian cancer (in a close relative before age 60)
  • You are currently under legal guardianship or have restrictions on your personal freedom (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 2
Sponsor
Centre Francois Baclesse
Registry
clinicaltrials_gov
Start date
1 April 2010
Est. completion
1 June 2012

Where this trial is recruiting

🇫🇷 France

Primary endpoints

estimate the proportion of patients with allelic imbalance at the level of expression of BRCA1

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov